Phylogeny  
Belongs to the TK group, RTK family, VEGF receptor (type V) sub-family (Stuttfeld & Ballmer-Hofer, 2009). Orthologues are reported in human, mouse, rat, chicken, Xenopus, and zebrafish. A single ancestral VEGFR-like receptor (D-VEGFR/PVR) is present in Drosophila, indicating early duplication/triplication events in vertebrate evolution (Shibuya & Claesson-Welsh, 2006; Stuttfeld & Ballmer-Hofer, 2009; Gordon et al., 2013).

Reaction Catalyzed  
ATP + protein-L-tyrosine ⇌ ADP + protein-L-tyrosine-phosphate (Roskoski, 2008).

Cofactor Requirements  
Catalysis requires Mg²⁺ for ATP phosphate coordination (Roskoski, 2008).

Substrate Specificity  
Autophosphorylation occurs on Y1230, Y1231, Y1265, Y1337 and Y1363 in VEGFR3 homodimers; in VEGFR3–VEGFR2 heterodimers only Y1230, Y1231 and Y1265 are modified (Lee et al., 2025). Phospho-Y1337 creates an SH2 docking site for SHC/GRB2 (Asthana, 2019). No consensus exogenous substrate motif has been defined (Roskoski, 2008).

Structure  
• Extracellular region comprises seven Ig-like domains; proteolytic cleavage within domain 5 leaves two disulphide-linked fragments that influence ligand access (Shibuya & Claesson-Welsh, 2006).  
• Single transmembrane helix (residues 776–797) followed by a juxtamembrane segment (798–844) (Roskoski, 2008).  
• Cytoplasmic portion contains a split, bilobed kinase domain; key catalytic residues include Lys868 (β3), Glu885 (αC), Asp1028 (HRD), and Asp1046 (DFG) (Roskoski, 2008).  
• Activation-segment phosphorylation stabilises the active conformation; overall folding is inferred from the closely related VEGFR2 because no FLT4 crystal structure is currently available (Roskoski, 2008).

Regulation  
• Ligand-induced autophosphorylation on Y1230/Y1231/Y1265/Y1337/Y1363 activates the receptor (Lee et al., 2025).  
• Heterodimerisation with VEGFR2 suppresses Y1337 and Y1363 phosphorylation, altering signalling specificity (Roskoski, 2008).  
• Integrin engagement activates c-Src, which can phosphorylate VEGFR3 independently of ligand binding (Asthana, 2019).  
• Extracellular cleavage in Ig-domain 5 modulates ligand responsiveness (Shibuya & Claesson-Welsh, 2006; Lee et al., 2025).  
• Alternative splicing yields a shorter C-terminal isoform lacking several autophosphorylation sites and displaying reduced signalling (Roskoski, 2008).

Function  
Expression – Broad endothelial expression during embryogenesis; post-natally restricted mainly to lymphatic endothelium, fenestrated capillaries and selected veins (Shibuya & Claesson-Welsh, 2006; Taipale et al., 1999).  
Upstream activators – VEGF-C and VEGF-D homodimers bind Ig-domains 1–2 and promote receptor dimerisation (Shibuya & Claesson-Welsh, 2006; Taipale et al., 1999).  
Downstream signalling – Phospho-Y1337 recruits SHC/GRB2 to trigger the RAS-MAPK cascade; PI3K-AKT supports survival; PKC contributes to ERK activation (Asthana, 2019; VEGF-A/VEGFRs system, 2022).  
Physiological roles – Essential for embryonic vascular remodelling (Vegfr3-null mice die at E9.5–E11) (Roskoski, 2008; Taipale et al., 1999); governs lymphangiogenesis, endothelial migration and sprouting in adult tissues (Shibuya, 2001; VEGF-A/VEGFRs system, 2022). Forms heterodimers with VEGFR2 to modulate KDR signalling output (Lee et al., 2025).

Inhibitors  
Small-molecule TKIs with activity toward VEGFR3 include MAZ51, tivozanib, axitinib, vandetanib and sorafenib; multi-targeted agents such as sunitinib and sorafenib inhibit VEGFR1-3 and PDGFRs (Asthana, 2019; Roskoski, 2008). Soluble receptor “ligand traps” that sequester VEGF-C/D act as decoy inhibitors (Lee et al., 2025).

Other Comments  
Loss-of-function FLT4 mutations cause congenital lymphoedema 1 (Milroy disease); >58 pathogenic variants, mainly kinase-domain missense changes, are reported (Gordon et al., 2013). The Chy mouse p.Ile1053Phe allele mirrors the human phenotype, and a recessive p.Ser1235Cys mutation produces mild hereditary lymphoedema (Melikhan-Revzin et al., 2015).

References  
Asthana, M. (2019). Structural and functional characterization of extracellular domains of vascular endothelial growth factor receptor 1 and 2 (pp. 33–36, 139–142). https://doi.org/10.5451/unibas-007168930  

Gordon, K., Spiden, S., Connell, F., Brice, G., Cottrell, S., Short, J., … Ostergaard, P. (2013). FLT4/VEGFR3 and Milroy disease: Novel mutations, a review of published variants and database update. Human Mutation, 34, 1–30. https://doi.org/10.1002/humu.22223  

Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025). Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives. Signal Transduction and Targeted Therapy, 10, 1–30. https://doi.org/10.1038/s41392-025-02249-0  

Melikhan-Revzin, S., Kurolap, A., Dagan, E., Mory, A., & Gershoni-Baruch, R. (2015). A novel missense mutation in FLT4 causes autosomal recessive hereditary lymphedema. Lymphatic Research and Biology, 13(2), 107–111. https://doi.org/10.1089/lrb.2014.0044  

Roskoski, R. (2008). VEGF receptor protein–tyrosine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 375, 287–291. https://doi.org/10.1016/j.bbrc.2008.07.121  

Shibuya, M. (2001). Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Structure and Function, 26(1), 25–35. https://doi.org/10.1247/csf.26.25  

Shibuya, M., & Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research, 312(5), 549–560. https://doi.org/10.1016/j.yexcr.2005.11.012  

Stuttfeld, E., & Ballmer-Hofer, K. (2009). Structure and function of VEGF receptors. IUBMB Life, 61, 915–922. https://doi.org/10.1002/iub.234  

Taipale, J., Mäkinen, T., Arighi, E., Kukk, E., Karkkainen, M., & Alitalo, K. (1999). Vascular endothelial growth factor receptor-3. Current Topics in Microbiology and Immunology, 237, 85–96. https://doi.org/10.1007/978-3-642-59953-8_5  

VEGF-A/VEGFRs system in neuropathies: A crossroad between pain and neuroprotection. (2022). Neurobiology Journal, 29–37.